FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W124547417> ?p ?o ?g. }

• W124547417 endingPage "173" @default.
• W124547417 startingPage "169" @default.
• W124547417 abstract "Delayed ischemic neurological deficit or clinical vasospasm remained a major cause for delayed neurological morbidity and mortality for patients with aneurysmal subarachnoid hemorrhage (SAH). Magnesium is a cerebral vasodilator. In experimental model of drug or SAH-induced vasospasm, magnesium blocks voltage-dependent calcium channels and reverses cerebral vasoconstriction. Furthermore, its antagonistic action on N-methyl-D-aspartate receptor in the brain prevents glutamate stimulation and decreases calcium influx during ischemic injury. Clinically, the protective effect of magnesium has also been found useful in women with preeclampsia, a condition thought to be due to cerebral vasospasm. Initial experimental result in human was found to safe and effective as compared to historical data. In our pilot study, 60 patients were randomly allocated to receive either magnesium sulfate infusion 80 mmol/day or saline infusion for 14 days. The incidence of symptomatic vasospasm decreased from 13/30(43%) in the saline group to 7/30(23%) in the patients receiving magnesium sulfate infusion, p = 0.10, odds ratio 0.398, 95% CI 0.131-1.211. Favorable outcome (Good recovery and moderate disability, as defined by Glasgow Outcome Scale) was achieved in 20 of 30 (67%) patients receiving magnesium sulfate infusion and 16 of 30 (53%) patients receiving placebo treatment, p = 0.292, odds ratio 1.750, 95% CI 0.616-4.974.From literature review, a total of 441 patients from four studies (including ours) were grouped for analysis. Using random effects model (Mantel-Haenszel, Robins-Breslow-Greenland), the pooled odds ratio for symptomatic vasospasm or delayed cerebral ischemia is, 0.620, 95% CI 0.389-0.987, statistically significant. Similarly, the pooled odds ratio for favorable outcome is 1.598, 95% CI 1.074-2.377, statistically significant. There are two multi-center phase III studies (IMASH and MASH2) being carried out to assess the clinical effects, in which IMASH has finished data collection on 30th June 2009." @default.
• W124547417 created "2016-06-24" @default.
• W124547417 creator A5006362128 @default.
• W124547417 creator A5027493491 @default.
• W124547417 creator A5035302026 @default.
• W124547417 creator A5065549183 @default.
• W124547417 date "2011-01-01" @default.
• W124547417 modified "2023-10-14" @default.
• W124547417 title "Intravenous Magnesium Sulfate After Aneurysmal Subarachnoid Hemorrhage: Current Status" @default.
• W124547417 cites W1976290551 @default.
• W124547417 cites W1977211256 @default.
• W124547417 cites W2007141103 @default.
• W124547417 cites W2015178727 @default.
• W124547417 cites W2019962183 @default.
• W124547417 cites W2143790244 @default.
• W124547417 cites W2156335402 @default.
• W124547417 cites W2167990168 @default.
• W124547417 cites W3149886588 @default.
• W124547417 cites W4250900558 @default.
• W124547417 doi "https://doi.org/10.1007/978-3-7091-0356-2_31" @default.
• W124547417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21125466" @default.
• W124547417 hasPublicationYear "2011" @default.
• W124547417 type Work @default.
• W124547417 sameAs 124547417 @default.
• W124547417 citedByCount "5" @default.
• W124547417 countsByYear W1245474172012 @default.
• W124547417 countsByYear W1245474172015 @default.
• W124547417 countsByYear W1245474172017 @default.
• W124547417 countsByYear W1245474172018 @default.
• W124547417 crossrefType "book-chapter" @default.
• W124547417 hasAuthorship W124547417A5006362128 @default.
• W124547417 hasAuthorship W124547417A5027493491 @default.
• W124547417 hasAuthorship W124547417A5035302026 @default.
• W124547417 hasAuthorship W124547417A5065549183 @default.
• W124547417 hasConcept C126322002 @default.
• W124547417 hasConcept C156957248 @default.
• W124547417 hasConcept C17624336 @default.
• W124547417 hasConcept C2776820941 @default.
• W124547417 hasConcept C2777736543 @default.
• W124547417 hasConcept C2777796830 @default.
• W124547417 hasConcept C2778506911 @default.
• W124547417 hasConcept C42219234 @default.
• W124547417 hasConcept C71924100 @default.
• W124547417 hasConceptScore W124547417C126322002 @default.
• W124547417 hasConceptScore W124547417C156957248 @default.
• W124547417 hasConceptScore W124547417C17624336 @default.
• W124547417 hasConceptScore W124547417C2776820941 @default.
• W124547417 hasConceptScore W124547417C2777736543 @default.
• W124547417 hasConceptScore W124547417C2777796830 @default.
• W124547417 hasConceptScore W124547417C2778506911 @default.
• W124547417 hasConceptScore W124547417C42219234 @default.
• W124547417 hasConceptScore W124547417C71924100 @default.
• W124547417 hasLocation W1245474171 @default.
• W124547417 hasLocation W1245474172 @default.
• W124547417 hasOpenAccess W124547417 @default.
• W124547417 hasPrimaryLocation W1245474171 @default.
• W124547417 hasRelatedWork W2013269907 @default.
• W124547417 hasRelatedWork W2028637529 @default.
• W124547417 hasRelatedWork W2039711219 @default.
• W124547417 hasRelatedWork W2090887360 @default.
• W124547417 hasRelatedWork W2274368259 @default.
• W124547417 hasRelatedWork W2466880199 @default.
• W124547417 hasRelatedWork W2617692001 @default.
• W124547417 hasRelatedWork W2764246278 @default.
• W124547417 hasRelatedWork W3031753334 @default.
• W124547417 hasRelatedWork W4297489586 @default.
• W124547417 isParatext "false" @default.
• W124547417 isRetracted "false" @default.
• W124547417 magId "124547417" @default.
• W124547417 workType "book-chapter" @default.